CLOs on the Move

Generex

www.generex.com

 
Generex Biotechnology has been engaged primarily in the research and development of drug delivery systems and technologies. Our primary focus has been our proprietary technology for the administration of formulations of large molecule drugs to the oral (buccal) cavity using a handheld aerosol applicator. Generex Biotechnology has a two business focuses: 1) implementing an acquisition strategy and 2) financing sponsored clinical trials. We are positioning ourselves as a diversified holding company involved in increasing our "pipeline" of compounds, therapies, treatments, diagnostics, and technologies in all stages in the FDA process through accretive acquisitions. We are also strategically aligning ourselves with ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.generex.com
  • 4145 North Service Road Suite 200
    Burlington, ON CAN L7L 6A3
  • Phone: 800.391.6755

Executives

Name Title Contact Details
Mark Fletcher
 Executive Vice President, General Counsel and Secretary Profile

Similar Companies

ShanghaiBio Corporation

ShanghaiBio Corporation is a North Brunswick, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Slingshot Biosciences

Making advanced diagnostics and adoptive cell therapies more accessible by working from the bottom up via synthetic cells.

IMV

IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases.

Curran Biotech

Curran Biotech is a materials manufacturing company that provides nano coatings to biochemical, chemical, energy and construction industries including water-repellent coatings for fabrics, canvas, tarps, and glass. Our hydrophobic coatings are specifically designed to improve the nature and quality of the substrates by preventing water-substrate interactions. The technology was developed in the materials/chemistry labs (Institute for Nano Energy) of the physics department at the University of Houston and started commercialization in 2013.

Turnstone Biologics

Turnstone Biologics, a privately held clinical stage biotech company, is developing breakthrough cancer immunotherapies by advancing two leading and complementary platforms that drive innate and adaptive tumor immunity, to provide benefit to the millions of cancer patients underserved by current treatment options. Turnstone`s proprietary vaccinia virus platform is engineered to drive coordinated immune activation, potent viral activity, and local expression of encoded therapeutics. The innovative TIL cell therapy platform leverages clinically validated treatment protocols and has been specifically designed to extend beyond the use of bulk TILs to enrich for the most relevant T-cells for tumor eradication, preserving broad antigen diversity and minimizing treatment times to patients. The Company has an ongoing Phase 1/2a trial in solid tumors (RAPTOR) for its leading oncolytic virus candidate, RIVAL-01, and is expecting to file an IND for the lead TIL therapy candidate, TIDAL-01, in 2021.